Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ECOR good moving and maybe major news around the corner
$ECOR gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)
Source: GlobeNewswire Inc.
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of two peer reviewed publications supporting the use of gammaCore (non-invasive vagal nerve stimulation; nVNS) in patients with posttraumatic stress disorder (PTSD). The first paper entitled “Effect of transcutaneous cervical vagus nerve stimulation on declarative and working memory in patients with Posttraumatic Stress Disorder (PTSD): A pilot study” was authored by Tilendra Choudhary and the second, “Transcutaneous vagal nerve stimulation modulates stress-induced plasma ghrelin levels: A double-blind, randomized, sham-controlled trial” was written by Kasra Moazzami. Both studies were conducted at Emory University and were published in the peer reviewed Journal of Affective Disorders.
The prevalence of PTSD in the United States is estimated at 10-12% in women and 5-6% in men, and the prevalence in veterans can be twice as high. PTSD is the third most common service-connected disorder in veterans and is associated with considerable morbidity and impairment in function. PTSD is associated with an increase in medical disorders and utilization of medical resources which places a significant emotional and economic burden on society. It is believed that many veterans do not seek or obtain appropriate treatment making it an important priority for the Veterans Administration (VA).
PTSD treatments, which include pharmacotherapy and psychotherapy, have many limitations for many veterans. Standard pharmaceutical treatments can have side effects and/or limited efficacy and half of veterans with PTSD drop out of psychotherapy treatments.
The study of 15 symptomatic subjects with a clinical diagnosis of PTSD suggested that transcutaneous vagus nerve stimulation (tcVNS) improves attention, and declarative and working memory, in patients with PTSD as measured by multiple endpoints. The study was conducted over the course of three months. The results show that the active group developed better attention and recall of paragraphs encoded with stimulation with a 91.4% improvement over the course of the study (p < 0.05) in paragraph recall. The study also showed a trend towards improvement in working memory tasks.1
The second study enrolled 55 subjects and the authors concluded that tcVNS could reduce the levels of ghrelin in response to various stressful stimuli. Ghrelin is a neuropeptide hypothesized to be involved in the stress response but also plays an important role in the regulation of appetite. Biomarkers that can be easily assessed can help identify likely responders to a specific therapy and are critical to improving the patient experience and decreasing health care costs. The results of this study showed that tcVNS, in conjunction with personalized traumatic scripts, resulted in lower ghrelin levels (265.2 ± 143.6 pg/ml vs 478.7 ± 349.2 pg/ml, P = 0.01). Additionally, after completing the public speaking and mental arithmetic tests, ghrelin levels were found to be lower in the group receiving tcVNS (293.3 ± 102.4 pg/ml vs 540.3 ± 203.9 pg/ml, P = 0.009).2 Ghrelin may be involved in behaviors like stress-induced over-eating, suggesting future avenues of research into the potential for nVNS in the treatment of obesity and possibly stress-induced eating disorders.
The senior co-author of both papers, Dr. Douglas Bremner, Professor of Psychiatry and Behavioral Sciences at Emory University and a Staff Physician at the Atlanta VA Medical Center, commented, “These two studies add to the growing body of evidence that tcVNS represents a promising new treatment for PTSD.” Dr. Bremner continued, “The identification of a possible biomarker that can be measured in plasma, with the demonstration of a marked improvement in memory after a stressful trigger, is an exciting advance for both clinicians and, most importantly, patients suffering from PTSD.”
Peter Staats, MD, Chief Medical Officer of electroCore, commented, “The impact of PTSD on millions of Americans including current warfighters and our Veterans is well understood. We desperately need new, safe, non-drug options and the data continues to suggest that gammaCore is a possible option. We thank Professors Bremner and Inan and their teams at Emory University, The Georgia Institute of Technology and the Atlanta VA for their tireless efforts to help their patients with PTSD.”
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans including potential commercial applications of gammaCore and nVNS for improved attention and declarative and working memory in patients with PTSD as well as their effect on stress-induced levels of ghrelin; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the issuance of U.S. and international patents, including patents related to non-invasive nerve stimulation with mobile devices, providing expanded IP coverage; the possibility of future business models, the potential of nVNS generally and gammaCore in particular and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
________________
1 Choudhary T, Elliott M, Euliano NR, Gurel NZ, Rivas AG, Wittbrodt MT, Vaccarino V, Shah AJ, Inan OT, Bremner JD. Effect of transcutaneous cervical vagus nerve stimulation on declarative and working memory in patients with Posttraumatic Stress Disorder (PTSD): A pilot study. J Affect Disord. 2023 Oct 15;339:418-425. doi: 10.1016/j.jad.2023.07.025. Epub 2023 Jul 12. PMID: 37442455.
2 Moazzami K, Pearce BD, Gurel NZ, Wittbrodt MT, Levantsevych OM, Huang M, Shandhi MMH, Herring I, Murrah N, Driggers E, Alkhalaf ML, Soudan M, Shallenberger L, Hankus AN, Nye JA, Vaccarino V, Shah AJ, Inan OT, Bremner JD. Transcutaneous vagal nerve stimulation modulates stress-induced plasma ghrelin levels: A double-blind, randomized, sham-controlled trial. J Affect Disord. 2023 Sep 14;342:85-90. doi: 10.1016/j.jad.2023.09.015. Epub ahead of print. PMID: 37714385.
Primary Logo
$ECOR gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)
Source: GlobeNewswire Inc.
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of two peer reviewed publications supporting the use of gammaCore (non-invasive vagal nerve stimulation; nVNS) in patients with posttraumatic stress disorder (PTSD). The first paper entitled “Effect of transcutaneous cervical vagus nerve stimulation on declarative and working memory in patients with Posttraumatic Stress Disorder (PTSD): A pilot study” was authored by Tilendra Choudhary and the second, “Transcutaneous vagal nerve stimulation modulates stress-induced plasma ghrelin levels: A double-blind, randomized, sham-controlled trial” was written by Kasra Moazzami. Both studies were conducted at Emory University and were published in the peer reviewed Journal of Affective Disorders.
The prevalence of PTSD in the United States is estimated at 10-12% in women and 5-6% in men, and the prevalence in veterans can be twice as high. PTSD is the third most common service-connected disorder in veterans and is associated with considerable morbidity and impairment in function. PTSD is associated with an increase in medical disorders and utilization of medical resources which places a significant emotional and economic burden on society. It is believed that many veterans do not seek or obtain appropriate treatment making it an important priority for the Veterans Administration (VA).
PTSD treatments, which include pharmacotherapy and psychotherapy, have many limitations for many veterans. Standard pharmaceutical treatments can have side effects and/or limited efficacy and half of veterans with PTSD drop out of psychotherapy treatments.
The study of 15 symptomatic subjects with a clinical diagnosis of PTSD suggested that transcutaneous vagus nerve stimulation (tcVNS) improves attention, and declarative and working memory, in patients with PTSD as measured by multiple endpoints. The study was conducted over the course of three months. The results show that the active group developed better attention and recall of paragraphs encoded with stimulation with a 91.4% improvement over the course of the study (p < 0.05) in paragraph recall. The study also showed a trend towards improvement in working memory tasks.1
The second study enrolled 55 subjects and the authors concluded that tcVNS could reduce the levels of ghrelin in response to various stressful stimuli. Ghrelin is a neuropeptide hypothesized to be involved in the stress response but also plays an important role in the regulation of appetite. Biomarkers that can be easily assessed can help identify likely responders to a specific therapy and are critical to improving the patient experience and decreasing health care costs. The results of this study showed that tcVNS, in conjunction with personalized traumatic scripts, resulted in lower ghrelin levels (265.2 ± 143.6 pg/ml vs 478.7 ± 349.2 pg/ml, P = 0.01). Additionally, after completing the public speaking and mental arithmetic tests, ghrelin levels were found to be lower in the group receiving tcVNS (293.3 ± 102.4 pg/ml vs 540.3 ± 203.9 pg/ml, P = 0.009).2 Ghrelin may be involved in behaviors like stress-induced over-eating, suggesting future avenues of research into the potential for nVNS in the treatment of obesity and possibly stress-induced eating disorders.
The senior co-author of both papers, Dr. Douglas Bremner, Professor of Psychiatry and Behavioral Sciences at Emory University and a Staff Physician at the Atlanta VA Medical Center, commented, “These two studies add to the growing body of evidence that tcVNS represents a promising new treatment for PTSD.” Dr. Bremner continued, “The identification of a possible biomarker that can be measured in plasma, with the demonstration of a marked improvement in memory after a stressful trigger, is an exciting advance for both clinicians and, most importantly, patients suffering from PTSD.”
Peter Staats, MD, Chief Medical Officer of electroCore, commented, “The impact of PTSD on millions of Americans including current warfighters and our Veterans is well understood. We desperately need new, safe, non-drug options and the data continues to suggest that gammaCore is a possible option. We thank Professors Bremner and Inan and their teams at Emory University, The Georgia Institute of Technology and the Atlanta VA for their tireless efforts to help their patients with PTSD.”
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans including potential commercial applications of gammaCore and nVNS for improved attention and declarative and working memory in patients with PTSD as well as their effect on stress-induced levels of ghrelin; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the issuance of U.S. and international patents, including patents related to non-invasive nerve stimulation with mobile devices, providing expanded IP coverage; the possibility of future business models, the potential of nVNS generally and gammaCore in particular and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
________________
1 Choudhary T, Elliott M, Euliano NR, Gurel NZ, Rivas AG, Wittbrodt MT, Vaccarino V, Shah AJ, Inan OT, Bremner JD. Effect of transcutaneous cervical vagus nerve stimulation on declarative and working memory in patients with Posttraumatic Stress Disorder (PTSD): A pilot study. J Affect Disord. 2023 Oct 15;339:418-425. doi: 10.1016/j.jad.2023.07.025. Epub 2023 Jul 12. PMID: 37442455.
2 Moazzami K, Pearce BD, Gurel NZ, Wittbrodt MT, Levantsevych OM, Huang M, Shandhi MMH, Herring I, Murrah N, Driggers E, Alkhalaf ML, Soudan M, Shallenberger L, Hankus AN, Nye JA, Vaccarino V, Shah AJ, Inan OT, Bremner JD. Transcutaneous vagal nerve stimulation modulates stress-induced plasma ghrelin levels: A double-blind, randomized, sham-controlled trial. J Affect Disord. 2023 Sep 14;342:85-90. doi: 10.1016/j.jad.2023.09.015. Epub ahead of print. PMID: 37714385.
Primary Logo
electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference
$2 is coming
They has zero product and just a shell to sale shares to uneducated people
Good job
Too risky and it will be below $10 soon
Nope….it will be less than $10
Getting worse that’s all I can tell
Thanks for sharing
Still a good one to hold
Evening Mick
Thanks God….my house in Tampa Bay is safe
I am almost 50 now
Let’s see how it play out. Maybe just another dream for $100 but missing a zero
This stock worth $5 not $50 IMO
I am semi-retire
Happy Sunday Mick
We need some rain here in Texas
Happy Weekend Mick
Thanks for sharing
Is this scam still alive? I thought it should be delisted by now
Short life as their car on the stock market
But now it is still a scam. What take over? Nothing to take over except selling shares and dump into uneducated investors on this scam company
$PMCB 100% SELL
https://www.barchart.com/stocks/quotes/PMCB/opinion
Dump and run away from this scam
$ECOR major insider buy
$ECOR heating up
$ECOR heating up
Is this scam still alive? How is the trade for $2.83?
Karma to KW. He should be in jail
$ECOR electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC
Source: GlobeNewswire Inc.
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that ReletexTM by Reliefband, the first and only FDA cleared non-invasive neuromodulation device available by prescription for nausea and vomiting, will be distributed and billed exclusively by electroCore, Inc. within the Department of Veterans Affairs (VA) and other Federal Supply Schedule (FSS) eligible entities.
“Reliefband is a leading innovator in wearable technology for the treatment of nausea and vomiting,” commented Rich Ransom, Chief Executive Officer of Reliefband Technologies. “Partnering with electroCore to distribute our prescription non-invasive, non-drug, neuromodulation device seemed like a natural fit. We are excited about the collaboration and hopeful the relationship will provide our veterans access to another FDA cleared non-drug solution.”
“We are thrilled to be offering the Reletex product within VA hospitals and other FSS eligible entities,” commented Dan Goldberger, Chief Executive Officer of electroCore. “We continue to build out our commercial sales organization and look for unique and complementary therapies which can be made available to our customer base. The drug-free, patient-controlled Reletex product is ideal for veterans suffering from nausea and vomiting and we believe it will be well adopted by customers who utilize neuromodulation devices such as our existing gammaCore™ therapy to treat medical conditions.”
About Reliefband Technologies, LLC
Reliefband is a world leader in neuromodulation and wearable technology. The company’s patented, clinically proven wearable solution quickly prevents and effectively treats nausea and vomiting. Its unique, FDA-cleared neuromodulation technology was originally developed for use in hospitals and alters nerve activity through targeted delivery of gentle pulses to the underside of the wrist to “turn off” feelings of nausea and vomiting. Reliefband is a drug-free alternative that eliminates the discomfort associated with nausea and vomiting. The Reliefband wearable solution has been an industry leader for more than 20 years and is available OTC, at Reliefband.com and Amazon.com.
About ReletexTM
Reletex is an advanced pulse generator that utilizes neuromodulation technology. It is the First-Class II neuromodulation device cleared by the FDA for the therapy of nausea and vomiting. Reletex is a single patient use device and can function with its included set of non-replaceable/non-rechargeable batteries for approximately 150 hours when used on setting 3. Reletex is available by prescription for the treatment of nausea and vomiting as an adjunct to antiemetics.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects through distribution of Reletex within the Department of Veterans Affairs or other FSS eligible entities or other new markets or other distribution agreements and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
$ECOR electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC
Source: GlobeNewswire Inc.
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that ReletexTM by Reliefband, the first and only FDA cleared non-invasive neuromodulation device available by prescription for nausea and vomiting, will be distributed and billed exclusively by electroCore, Inc. within the Department of Veterans Affairs (VA) and other Federal Supply Schedule (FSS) eligible entities.
“Reliefband is a leading innovator in wearable technology for the treatment of nausea and vomiting,” commented Rich Ransom, Chief Executive Officer of Reliefband Technologies. “Partnering with electroCore to distribute our prescription non-invasive, non-drug, neuromodulation device seemed like a natural fit. We are excited about the collaboration and hopeful the relationship will provide our veterans access to another FDA cleared non-drug solution.”
“We are thrilled to be offering the Reletex product within VA hospitals and other FSS eligible entities,” commented Dan Goldberger, Chief Executive Officer of electroCore. “We continue to build out our commercial sales organization and look for unique and complementary therapies which can be made available to our customer base. The drug-free, patient-controlled Reletex product is ideal for veterans suffering from nausea and vomiting and we believe it will be well adopted by customers who utilize neuromodulation devices such as our existing gammaCore™ therapy to treat medical conditions.”
About Reliefband Technologies, LLC
Reliefband is a world leader in neuromodulation and wearable technology. The company’s patented, clinically proven wearable solution quickly prevents and effectively treats nausea and vomiting. Its unique, FDA-cleared neuromodulation technology was originally developed for use in hospitals and alters nerve activity through targeted delivery of gentle pulses to the underside of the wrist to “turn off” feelings of nausea and vomiting. Reliefband is a drug-free alternative that eliminates the discomfort associated with nausea and vomiting. The Reliefband wearable solution has been an industry leader for more than 20 years and is available OTC, at Reliefband.com and Amazon.com.
About ReletexTM
Reletex is an advanced pulse generator that utilizes neuromodulation technology. It is the First-Class II neuromodulation device cleared by the FDA for the therapy of nausea and vomiting. Reletex is a single patient use device and can function with its included set of non-replaceable/non-rechargeable batteries for approximately 150 hours when used on setting 3. Reletex is available by prescription for the treatment of nausea and vomiting as an adjunct to antiemetics.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects through distribution of Reletex within the Department of Veterans Affairs or other FSS eligible entities or other new markets or other distribution agreements and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
All I can say is “SCAM”
Wow….more shares issue so they can dump it again
“to approve a proposed amendment to the PharmaCyte Biotech, Inc. articles of incorporation, as amended, to increase the number of authorized shares of common stock from 133,333,334 to 200,000,000; and”
Swing trader paradise for this scam company
Nice close today